AngioDynamics (ANGO) Q3 2024: MedTech Revenue Climbs 13% as Portfolio Streamlines for Margin Upside
AngioDynamics’ Q3 marked a pivotal inflection as MedTech outpaced MedDevice, driven by NanoKnife and Arion, while portfolio divestitures and a shift to outsourced manufacturing realigned the business for higher growth and profitability. The AlphaVac pulmonary embolism indication and strong international expansion signal a more focused, innovation-led trajectory, though near-term gross margin remains volatile as the company transitions its operating model. Investors should watch for the full impact of the portfolio reset and the ramp of new launches as the company pivots to a leaner, MedTech-centric platform.
Summary
- MedTech Outpaces Legacy Devices: Core MedTech platforms now anchor growth, with NanoKnife and Arion gaining share.
- Portfolio Overhaul Targets Margin Expansion: Divestitures and manufacturing outsourcing streamline complexity, setting up for improved profitability.
- AlphaVac Approval Unlocks New Market: Pulmonary embolism indication and upcoming launches reshape the growth runway.
Business Overview
AngioDynamics is a medical technology company specializing in minimally invasive therapies for vascular and oncology markets. The business operates in two primary segments: MedTech, higher-growth, innovation-focused platforms (such as NanoKnife, AlphaVac, Arion), and MedDevice, legacy device products (e.g., EVLT, angiographic catheters). Revenue is generated from product sales to hospitals, clinics, and international distributors, with MedTech now comprising nearly 39% of revenue post-divestiture.
Performance Analysis
Q3 saw a decisive return to double-digit MedTech growth, led by NanoKnife (up 47%) and Arion (up 15%), while MedDevice delivered steady mid-single-digit gains. International markets were a highlight, with MedTech sales up 53% overseas, reflecting both product momentum and the impact of targeted clinical education events. However, mechanical thrombectomy (AngioVac and AlphaVac) declined 12% as AlphaVac sales paused during the APEX PE trial wind-down, though FDA clearance for the pulmonary embolism indication arrived ahead of schedule.
Gross margin contracted by 290 basis points YoY, reflecting adverse product and geographic mix and the transitional costs of shifting manufacturing out of upstate New York. The company’s aggressive portfolio pruning—divesting low-growth, lower-margin businesses—has improved the underlying margin profile, but the transition to a fully outsourced model introduces temporary volatility. Cash flow was pressured by operating losses and inventory build, but the balance sheet is now debt-free with $78.5 million in cash, following asset sales at a two-times revenue multiple.
- NanoKnife and Arion Drive MedTech Gains: These platforms now anchor the growth narrative, with robust capital and disposable sales.
- Mechanical Thrombectomy Reset: AlphaVac’s PE approval sets up a new market entry, but short-term softness persists until the full launch in Q1 FY25.
- Margin Volatility: Gross margin remains noisy as the company double-pays for overhead during the manufacturing transition, but long-term expansion is expected as MedTech mix rises.
Overall, AngioDynamics’ Q3 results reflect a business in active transformation, with near-term noise masking the underlying shift toward a higher-growth, higher-margin platform.
Executive Commentary
"We executed on a number of significant strategic milestones during and after Q3, including securing an expanded indication and reaching a settlement agreement with BD Bard. Additionally, we announced another significant step in the optimization of our portfolio with the divestiture of our PICC and midline product portfolios."
Jim Clemmer, President and Chief Executive Officer
"Our transition incorporates moving manufacturing to third-party partners. The faster we do this, the quicker we end up double paying for manufacturing overhead and therefore increasing the impact of underabsorption in our Queensberry manufacturing plant. The right thing to do in connection with our plan, but we cannot fully recognize the impact of our overhead savings until the full transition is complete."
Steve Trowbridge, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. MedTech Platform Focus
The divestiture of lower-growth, lower-margin businesses (PICC, midline, dialysis, and older RF products) has sharpened AngioDynamics’ focus on its three core MedTech platforms: NanoKnife, AlphaVac, and Arion. These platforms are positioned for organic growth, with NanoKnife benefiting from rising prostate cancer adoption and AlphaVac now cleared for pulmonary embolism treatment.
2. Manufacturing Outsourcing for Margin Expansion
The transition to a fully outsourced manufacturing model is underway, targeting $15 million in annualized savings by FY27. While this creates near-term gross margin noise due to overhead duplication, the structural shift is expected to unlock long-term margin expansion and operational flexibility.
3. International Growth and Clinical Education
International sales surged 21% overall, with MedTech up 53%, supported by clinical symposia and the upcoming CE mark for Arion. The company is building a pipeline of global physicians, leveraging education to accelerate adoption and diversify revenue sources.
4. Litigation and Balance Sheet Clarity
The settlement with BD Bard resolves decade-long IP litigation, removing an overhang and allowing management to redeploy resources to growth initiatives. The company is now debt-free, with a strong cash position to fund organic investments.
5. Clinical Data and Pipeline Catalysts
APEX trial results for AlphaVac exceeded expectations, positioning the device as a differentiated entrant in the PE market. Upcoming data releases and regulatory milestones (including NanoKnife for prostate) will be key catalysts through 2024 and into 2025.
Key Considerations
This quarter’s results reflect a strategic reset, with management taking bold actions to align the business with higher-growth, higher-margin opportunities. Investors should weigh near-term operational turbulence against the long-term benefits of the transformation.
Key Considerations:
- MedTech Mix Shift: As MedTech approaches 40% of revenue, overall growth and profitability should improve, but execution risk remains during the transition.
- Gross Margin Headwinds: Manufacturing outsourcing introduces near-term volatility; true margin expansion will only materialize as the transition completes by FY27.
- AlphaVac Launch Execution: The PE indication opens a large new market, but commercial success will depend on disciplined training and sales force ramp-up.
- Cash Utilization: Operating losses and inventory build will pressure cash in the near term, though the balance sheet is fortified by divestiture proceeds and zero debt.
Risks
Execution risk is elevated as AngioDynamics juggles multiple transitions—portfolio divestitures, manufacturing outsourcing, and commercial launches—simultaneously. Gross margin volatility may persist longer than anticipated if the manufacturing shift encounters delays. Competitive intensity in thrombectomy and prostate ablation markets could pressure pricing or slow adoption. The loss of cash-accretive legacy businesses may also challenge free cash flow until MedTech platforms scale further.
Forward Outlook
For Q4 and FY24, AngioDynamics guided to:
- Revenue of $270 to $275 million, reflecting the impact of recent divestitures and discontinued products.
- Full-year adjusted loss per share of $0.54 to $0.58, with gross margin now expected at 52% to 54% (up from prior 49% to 51%).
Management highlighted several factors that will shape the next phase:
- MedTech revenue growth guided at 10% to 15%, with MedDevice at 2% to 4%.
- Gross margin will remain volatile until the manufacturing transition is fully executed, but underlying margin profile is improving post-divestiture.
Takeaways
AngioDynamics is executing a high-conviction pivot toward MedTech, with streamlined operations, a stronger balance sheet, and new product indications setting up a multi-year growth runway.
- Portfolio Realignment: Divestitures and discontinued products have simplified the business, focusing capital and management attention on scalable, differentiated MedTech platforms.
- Margin and Cash Dynamics: Gross margin expansion and cash flow improvement are delayed by near-term transition costs, but structural improvements are in place for FY26 and beyond.
- Pipeline and Launches: AlphaVac’s PE approval and upcoming NanoKnife prostate data are key inflection points that could accelerate adoption and growth in FY25.
Conclusion
AngioDynamics’ Q3 marks a turning point as the company leans into its MedTech strengths, sheds legacy drag, and prepares for a new phase of growth and profitability. While operational noise will persist in the near term, the strategic reset is positioning the business for long-term value creation.
Industry Read-Through
AngioDynamics’ transformation underscores a broader medtech trend: legacy device businesses are increasingly divesting commoditized assets and doubling down on differentiated, high-growth platforms. The company’s move to a fully outsourced manufacturing model reflects a sector-wide push for asset-light operations, though near-term margin volatility is a common transitional challenge. AlphaVac’s rapid approval for PE and the strong international MedTech growth highlight the importance of clinical data, regulatory agility, and global physician engagement in driving adoption. Investors in the vascular and oncology device space should monitor similar portfolio streamlining and innovation-led pivots across the sector.